Validation of Risk Stratification for Cardiac Events in Pregnant Women With Valvular Heart Disease
Authors' conclusion
In pregnant patients with VHD, DEVI and CARPREG-II scores showed good discriminative ability and clinical utility across a range of probabilities. The DEVI score showed better agreement between predicted probabilities and observed events.
Study context
- Population
- Pregnancies complicated with valvular heart disease (VHD), tertiary centre in a middle-income setting, January 2019 to April 2022
- Participants
- 577 eligible pregnancies
- Comparison
- DEVI vs CARPREG-II risk scores
- Outcome
- Adverse composite cardiac events
Methodological detailscohort study, consecutive pregnancies, single tertiary centre, middle-income setting
- Cohort study
- Consecutive pregnancies
- Single tertiary centre
- Middle-income setting
Performance
As reported in the abstract
Discrimination for adverse composite cardiac events
| Test or model | AUC |
|---|---|
| DEVI | 0.884 (95% CI: 0.844-0.923) |
| CARPREG-II | 0.808 (95% CI: 0.753-0.863) |
AUC
DEVI0.884 (95% CI: 0.844-0.923)
CARPREG-II0.808 (95% CI: 0.753-0.863)
- Composite outcome events
- 69 (12.1%)
- Decision curve analysis: both models useful across predicted probability thresholds
- 10% and 50%
Original publication
Validation of Risk Stratification for Cardiac Events in Pregnant Women With Valvular Heart Disease. J Am Coll Cardiol. Published 3 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →